Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study
Open Access
- 6 November 2025
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (1) , 102770
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialAnnals of Oncology, 2023
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerNew England Journal of Medicine, 2019
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2019
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerJournal of Clinical Oncology, 2019
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survivalAnnals of Oncology, 2017
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialThe Lancet Oncology, 2015
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Identification of patient groups at highest risk from traditional approach to ovarian cancer treatmentGynecologic Oncology, 2011